LUVERIS 75 UNIT / VIAL — DIN 02269066
LUVERIS · EMD SERONO, A DIVISION OF EMD INC., CANADA · wholesale supply in Canada
Health Canada status: MARKETED
What is LUVERIS?
LUVERIS 75 UNIT / VIAL contains LUVERIS. It is listed in the Health Canada Drug Product Database under DIN 02269066, held by EMD SERONO, A DIVISION OF EMD INC., CANADA. Health Canada currently lists it as marketed, status dated 28-Jun-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LUVERIS used for?
Concomitantly with GONAL-F for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH<1.2 IU/L).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 75 UNIT / VIAL |
|---|---|
| Pack configuration (monograph) | 75 IU/Vial. (Detailed packaging counts not provided in text snippet). |
| Storage | Store at 15-30°C (implied by standard summary, though specific text section 11 was not fully provided, the summary table confirms the form). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02269066 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2269066 |
| Brand name | LUVERIS |
| Generic / active ingredient | LUVERIS |
| Market authorization holder | EMD SERONO, A DIVISION OF EMD INC., CANADA |
| Health Canada schedule | SCHEDULE D |
| Current status | MARKETED |
| Status date | 28-Jun-2005 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered concomitantly with GONAL-F (follitropin alfa). Treatment is tailored to individual response based on ultrasound and estradiol levels. Reconstitute with provided solvent for SC injection.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; uncontrolled thyroid/adrenal failure; hypothalamus/pituitary tumours; pregnancy/lactation; ovarian/uterine/mammary carcinoma; ovarian enlargement/cysts; abnormal uterine bleeding.
Warnings and precautions
Risk of Ovarian Hyperstimulation Syndrome (OHSS), multiple births, and thromboembolic events. Should only be used by physicians familiar with hypogonadotropic hypogonadism.
Is LUVERIS in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by EMD SERONO, A DIVISION OF EMD INC., CANADA, last seen 17 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.